Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Chief Medical Officer | March 17, 2026 | March 19, 2026 |
| FATE THERAPEUTICS INCFATE · Entity 5968 | Chief Medical Officer | April 18, 2023 | April 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytomX Therapeutics, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 189,446 |
Reported balance
After 2026-03-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-17 · Sale · Disposed 21,279 · Balance 189,446 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2: Includes 149,833 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
F2: Includes 149,833 RSUs.
FATE THERAPEUTICS INC
Report date April 18, 2023 · Filed April 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 140,676 |
Ending reported balance
After 2023-04-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-04-18 · Sale · Disposed 215 · Balance 142,993 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the Reporting Person on April 15, 2019. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2: Represents the weighted average sale price of the shares sold from $6.46 to $6.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2-3. Row 2 · 2023-04-18 · Sale · Disposed 2,317 · Balance 140,676 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the Reporting Person on April 15, 2019. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F3: Represents the weighted average sale price of the shares sold from $6.56 to $6.60 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the Reporting Person on April 15, 2019. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
F2: Represents the weighted average sale price of the shares sold from $6.46 to $6.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2-3.
F3: Represents the weighted average sale price of the shares sold from $6.56 to $6.60 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2026 Filed Mar 19, 2026 18:41 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 21,279 | $6.42 | $136,675.02 |
DisclosureSEC source: 0001610717-26-000125 · form4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,446 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes 149,833 RSUs. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:27 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001610717-26-000042 · form4.xml · derivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-02-01 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:27 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000042 · form4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,725 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Includes 206,000 RSUs. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 18:39 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000356 · form4.xml · derivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 43,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 18:39 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001610717-25-000356 · form4.xml · derivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2035-09-25 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 16:32 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,025 | $0.60 | $2,410.98 |
DisclosureSEC source: 0001610717-25-000084 · form4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,725 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). F2 · balance_after: Includes 131,000 RSUs. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001610717-25-000018 · form4.xml · derivative · entry 4 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2035-02-03 F5 · derivative.exercise_date: 1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 238,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001610717-25-000018 · form4.xml · derivative · entry 3 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,000 Underlying: Common Stock · 238,000 shares Expires 2035-02-03 F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000018 · form4.xml · nonDerivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,750 F2 · shares: Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date. F3 · balance_after: Includes 139,750 RSUs. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 17:55 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000018 · form4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,250 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 20:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000031 · form4.xml · derivative · entry 3 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F4 · derivative.exercise_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. F4 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 20:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 122,500 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0001610717-24-000031 · form4.xml · derivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,500 Underlying: Common Stock · 122,500 shares Expires 2034-01-17 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 20:37 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000031 · form4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: Includes 26,250 RSUs. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 17:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001610717-23-000208 · form4.xml · derivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2033-07-18 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the one year anniversary measured from July 19, 2023 (the "Vesting Commencement Date"), and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 16:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,317 | $6.58 | $15,245.86 |
DisclosureSEC source: 0001209191-23-024820 · doc4.xml · nonDerivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,676 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the Reporting Person on April 15, 2019. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold from $6.56 to $6.60 per share. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 16:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 215 | $6.52 | $1,401.80 |
DisclosureSEC source: 0001209191-23-024820 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,993 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the Reporting Person on April 15, 2019. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold from $6.46 to $6.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2-3. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 16:13 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0001209191-23-007497 · doc4.xml · derivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2033-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2023, such that all of the shares shall be fully vested and exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 16:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 7,825 | $5.24 | $41,003.00 |
DisclosureSEC source: 0001209191-23-002974 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,208 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $5.12 to $5.34 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 16:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 4,062 | $35.37 | $143,672.94 |
DisclosureSEC source: 0001209191-22-025159 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,033 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold from $35.10 to $35.50 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:37 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 53,058 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000899243-22-003448 · doc4.xml · derivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,058 Underlying: Common Stock · 53,058 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:37 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 33,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003448 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,095 F1 · security: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 418 | $49.10 | $20,523.80 |
DisclosureSEC source: 0001209191-22-003166 · doc4.xml · nonDerivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,793 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $48.71 to $49.25 per share. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 3,547 | $48.44 | $171,816.68 |
DisclosureSEC source: 0001209191-22-003166 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,211 F1 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020 and 4,503 shares of Common Stock underlying RSUs granted to the reporting person on January 20, 2021. These sales were made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $47.68 to $48.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · derivative · entry 9 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 7,500 shares Expires 2029-04-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F8 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on April 15, 2020 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 5 | $55.54 | $277.70 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 8 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,758 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 600 | $54.58 | $32,748.00 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 7 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,763 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F7 · price: Represents the weighted average sale price of the shares sold ranging from $54.33 to $54.98 per share. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,031 | $53.66 | $55,323.46 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 6 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,363 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F6 · price: Represents the weighted average sale price of the shares sold ranging from $53.10 to $54.02 per share. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,822 | $52.37 | $95,418.14 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 5 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,394 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $52.09 to $52.87 per share. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,045 | $51.08 | $53,378.60 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 4 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,216 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $50.96 to $51.22 per share. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 900 | $50.42 | $45,378.00 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 3 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,261 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $49.96 to $50.89 per share. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,097 | $49.32 | $103,424.04 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,161 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $48.95 to $49.87 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 7. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 17:53 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 7,500 | $16.32 | $122,400.00 |
DisclosureSEC source: 0001209191-21-069313 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 17:38 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 60,958 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066156 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,758 F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 16:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,500 | $84.41 | $126,615.00 |
DisclosureSEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 3 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,800 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.635 to $84.61 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 16:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 900 | $82.91 | $74,619.00 |
DisclosureSEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 2 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,300 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.6175 to $83.23 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 16:00 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 875 | $81.80 | $71,575.00 |
DisclosureSEC source: 0001209191-21-027545 · doc4.xml · nonDerivative · entry 1 Chu Yu-Waye · CIK 0001854586 · Senior VP Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,200 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the reporting person on April 15, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.395 to $82.205 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.